ACMT Position Statement: Medical Toxicology Considerations in the Diagnosis and Treatment of Patients with Concerns About Mold-Related Inhalation Exposures
ACMT Position Statement: Medical Toxicology Considerations in the Diagnosis and Treatment of Patients with Concerns About Mold-Related Inhalation Exposures
August 13, 2025
Statement Authors: Authors: Jerrold Leikin,MD; Michael G. Holland,MD; Thomas L. Kurt, MD, MPH; Charles A. McKay, MD; Andrew I. Stolbach, MD, MPH
The position of the American College of Medical Toxicology (ACMT), is as follows:
The American College of Medical Toxicology (ACMT) is a professional society of physician toxicologists who focus on the diagnosis, management and prevention of acute and chronic health effects due to medications, chemicals, occupational and environmental toxins, and biological hazards. ACMT reaffirms its support and endorsement of the Institute of Medicine- now the National Academy of Medicine (NAM) - report on Damp Indoor Spaces and Health. (1) Although this position statement was not reaffirmed by NAM, we continue to support their 2004 position.
ACMT has prepared additional background and comments relating to this document and the more recently-released “Medical clinical diagnostics for indoor mold exposure” update from a group of twelve German health societies and organizations (AWMF). (2) Due to the increasing frequency of inquiries regarding this issue, ACMT is updating this position statement to reflect and incorporate recent studies while providing a best-practice approach from a Medical Toxicology perspective.
ACMT agrees with NAM and AWMF in recognition that damp indoor spaces present health risks to humans, in association with allergic mechanisms resulting from fungi, dust mites, bacteria, cockroaches, and possibly other antigens that proliferate in moist environments. ACMT concurs with these organizations, that residences, schools, offices, and other buildings should be designed to prevent water intrusion, and that when water damage or chronic moisture is identified it should be remediated as soon as possible.
While the allergic effects of fungi are well-summarized in these reports, there are still a number of misperceptions relating to mycotoxins or other chemicals produced by certain species of fungi, and their role in adverse health effects from exposures in water-damaged buildings. Although several epidemiological studies of building-related illness have implicated mycotoxins as a cause of health effects in water-damaged environments, their interpretation is complicated by limitations in their study design, exposure and dose assessment methods, and confounding effects. In fact, these issues have cast doubt on the causative role of inhaled mycotoxins for any toxic health effects in the indoor residential environment. (3-8)
ACMT believes that an improved understanding of the role of mycotoxins in damp indoor spaces should begin by acknowledging that both fungi and their mycotoxin products are ubiquitous in the outdoor environment. Human exposure to fungi can occur from contact with the soil as well as outdoor air, where fungal spores are normally present in much higher concentrations than indoor environments (with seasonal variability, e.g. cold, snow). Epidemiological studies of mold in indoor environments should include appropriate comparisons with outdoor air, and studies should be designed to consider our aggregate and cumulative exposure to fungi and mycotoxins from indoor and outdoor environments.
ACMT emphasizes the importance of distinguishing exposure to mycotoxins from exposure to the fungi that are capable of producing them. Toxigenic fungi and mycotoxins are not synonymous hazards. It is well established that for many fungal species, the production of mycotoxins is significantly influenced by genetics and the environmental conditions of their growth. The isolation of a toxigenic fungal species in the environment does not necessarily indicate that mycotoxins are also present, or that they are present at doses that pose health risks from environmental exposure. For this reason, if epidemiological studies of damp indoor spaces are to include hypotheses relating to mycotoxins, then exposure assessment methods should utilize validated techniques to detect and quantify mycotoxins directly in environmental samples. The interpretation of such environmental measurements should consist of a plausible, complete exposure pathway and an assessment of the dose-response relationship.
ACMT would also like to emphasize the importance of acknowledging that the diet is the most important source of human exposure to mycotoxins. The vast majority of scientific data on the adverse health effects of mycotoxins is derived from their presence as natural and unavoidable contaminants of foods and beverages that are consumed as part of a healthy diet. Mycotoxins of known dietary importance include aflatoxins (in corn, ground nuts, and dairy products), trichothecenes (in corn, cereals and fermented beverages) and ochratoxins (in coffee, wine, and dried fruits). Risk assessments have been conducted for several mycotoxins that are of relevance to human health,(9, 10) and these studies should be used as a benchmark for interpreting the relative role of exposures occurring from other sources and pathways in addition to dietary ingestion.
With respect to mycotoxins in indoor air, these compounds are large, complex molecules that are not volatile and their concentrations in indoor and outdoor air are exceedingly low. Exposure modeling studies have concluded that even in moldy environments, the maximum inhalation dose of mycotoxins is generally orders of magnitude lower than demonstrated thresholds for adverse health effects.(4, 11-12) The results of human studies in agricultural environments provide additional consistency for this finding, demonstrating that in moldy environments inhalation exposure to mycotoxins results in a dose that is far less than what is normally encountered from dietary exposure.(8, 13-14) Studies that quantify human exposure utilizing validated biomarkers as indicators of internal dose will provide additional information to assess cumulative exposure to mycotoxins. There have been significant advances in the research on biomarkers of exposure to important mycotoxins, (10, 15-17) and ACMT recommends that future studies utilize these methods in the assessment of the dose-response relationship, bearing in mind the variably short elimination half-life of most mycotoxins. It is inappropriate to attribute identification of mycotoxins in urine to postulated remote inhalation exposure.(18,19)
ACMT is aware of other types of clinical laboratory tests that have recently been utilized in epidemiological studies of damp indoor spaces, including “mycotoxin antibody testing.” Identification or measurement of antibodies to mycotoxins, rather than biomonitoring of mycotoxins directly, is not an accepted method to assess human exposure. This method has not been validated in well-designed epidemiological studies, and is not recommended for the assessment of human exposure to mycotoxins.(20) Fungal immunoassay tests (including immunoglobulin testing for IgG and IgE) can be clinically useful in the assessment of immunological conditions from exposure to fungal antigens (including common allergies and hypersensitivity pneumonitis), but they do not provide any information about the source or magnitude of exposure to mycotoxins and therefore they have no role in exposure assessment in this context. The American Academy of Asthma, Allergy, and Immunology (AAAAI) has addressed some of these issues in their position statement on health effects from mold exposure (21), as has the AWMF in a “key points” summary (22) of their 2023 update.(2)
In comparison to the ubiquitous low-level indoor exposures of concern to the general public , a syndrome known as Organic Dust Toxic Syndrome (ODTS) has been described in association with massive exposures to microbial elements and byproducts in agricultural environments, consisting of fever, malaise, myalgia, headache, dyspnea, chest tightness, dry cough, and nausea.(23, 24) While the pathogenesis of this transient condition is not completely understood, it has been hypothesized to develop from acute inhalation exposure to high concentrations of bacterial endotoxins, fungal mycotoxins, and possibly other cellular components of microorganisms that proliferate in agricultural environments. The epidemiology of this disorder is uncertain, but the levels of microbial exposure that have been measured in association with its occurrence are generally orders of magnitude greater than what has been measured in moldy home, school, or office environments. This syndrome is also known as “silo unloaders disease”, for its association with extreme airborne dust in agricultural environments. Descriptions of case reports and case series describe airborne dusts so thick that it was difficult to see across the room. It should be noted that symptoms from ODTS are usually transient in nature, and generally resolve within hours to days from the time of acute exposure.(24) There is no documented evidence that inhalation exposure to fungi or mycotoxins in indoor environments causes a chronic toxic encephalopathy.
Similarly, the role of volatile organic compounds produced by mold (mVOCs), which are responsible for the musty odor, can be addressed from a toxicological perspective. In sufficient doses, mVOCs can produce transient irritative symptoms and subjective complaints such as nasal and eye discomfort, headache and dizziness. However, the concentrations of mVOCs produced by mold in indoor spaces are very low, on the order of micrograms-to-nanograms per liter or part per billion (ppb) to parts per trillion (ppt) range (25). On the other hand, the levels that can induce sensory irritation are in the milligram per cubic meter (mg/m3) or parts per billion (ppb) range in the air. (26) By nature of their volatility, these compounds have short environmental half-lives (minutes to hours), and their effects are transient. When individuals complain of persistent neurological, cognitive, or non-specific symptoms weeks or months after the putative exposure, these symptoms should not be attributed to irritant effects; rather, other causes should be sought.(19, 27)
In summary, ACMT generally concurs with the NAM and AWM assessment of the relationship between damp indoor spaces and human health effects. ACMT recommends that public health responses to damp indoor spaces be based upon what is known and generally accepted with respect to their association with allergic disease.(28-31) Public health responses should not be solely based upon the presence of fungi or mycotoxins, because from a toxicological perspective, the available scientific evidence does not provide any compelling data to conclude that they pose significant health risks via inhalation in these settings,(2) The risks from inhalation exposure are minimal in comparison to other sources and pathways, including the diet, which in themselves are rarely of health consequence in the United States. Furthermore, the use of unapproved diagnostic studies and therapeutic modalities (i.e., to “detoxify”) based on unproven infection or mold – related toxicity (as opposed to allergic phenomena) are medically inappropriate and costly.(2, 32) In conclusion, there are no medical toxicologically-based diagnostic laboratory or treatment modalities in the management of individuals exposed to damp indoor spaces that are supportive of inhalation contact with mycotoxins as a systemic toxicant associated with mold/fungi.(7, 22, 27)
Disclaimer
While individual practices may differ, this is the position of the American College of Medical Toxicology at the time written, after a review of the issue and pertinent literature.
References
1) Institute of Medicine, Committee on Damp Indoor Spaces and Health. Damp Indoor Spaces and Health. Washington, D.C: National Academies Press; 2004. https://nap.nationalacademies.org/catalog/11011/damp-indoor-spaces-and-health
2) Hurraß J, Heinzow B, Walser-Reichenbach S, Aurbach U, Becker S, et al. AWMF mold guideline “Medical clinical diagnostics for indoor mold exposure”–Update 2023 AWMF Register No. 161/001. Allergologie Select 8 (2024):90. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097193/pdf/allergologieselect-8-090.pdf
3) Update: Pulmonary hemorrhage/hemosiderosis among infants--Cleveland, Ohio, 1993-1996. MMWR Morb Mortal Wkly Rep 2000 March 10;49(9):180-4. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a3.htm
4) American College of Occupational and Environmental Medicine. Evidence Based Statement: Adverse Human Health Effects Associated with Molds in the Indoor Environment. JOEM 2003;45(5):4700-478.
(5) Fung F, Clark RF. Health effects of mycotoxins: a toxicological overview. J Toxicol Clin Toxicol 2004;42(2):217-34.
(6) Page EH, Trout DB. The role of Stachybotrys mycotoxins in buildings related illness. AIHAJ 2001 September;62(5):644-8.
7) Chang, C., Gershwin, M.E. The Myth of Mycotoxins and Mold Injury. Clinic Rev Allerg Immunol 2019; 57:449–455. https://doi.org/10.1007/s12016-019-08767-4
8) Marcelloni AM, Pigini D, Chiominto A, Gioffrè A, Paba A. Exposure to airborne mycotoxins: the riskiest working environments and tasks, Ann Work Exposures Health 2024;68(1):19–35. https://doi.org/10.1093/annweh/wxad070
9) Food and Agriculture Organization/ United Nations Expert Committee on Food Additives. Safety evaluation of certain mycotoxins in food. Geneva: World Health Organization; 2001. https://www.inchem.org/documents/jecfa/jecmono/v47je01.htm
10) Bui-Klimke TR, Wu F. Ochratoxin A and human health risk: a review of the evidence. Crit Rev Food Sci Nutri 2015;55(13):1860-1869. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247821/pdf/nihms564584.pdf
11) Kelman BJ, Robbins CA, Swenson LJ, Hardin BD. Risk from inhaled mycotoxins in indoor office and residential environments. Int J Toxicol 2004 January;23(1):3-10.
12) Islam Z, Harkema JR, Pestka JJ. Satratoxin G from the black mold Stachybotrys chartarum evokes olfactory sensory neuron loss and inflammation in the murine nose and brain. Environmental Health Perspectives. http://dx.doi.org/10.1289/ehp.8854
13) Halstensen AS, Nordby KC, Elen O, Eduard W. Ochratoxin A in grain dust--estimated exposure and relations to agricultural practices in grain production. Ann Agric Environ Med 2004;11(2):245-54.
14) Skaug MA. Levels of ochratoxin A and IgG against conidia of Penicillium verrucosum in blood samples from healthy farm workers. Ann Agric Environ Med 2003;10(1):73-7.
15) Gilbert J, Brereton P, MacDonald S. Assessment of dietary exposure to ochratoxin A in the UK using a duplicate diet approach and analysis of urine and plasma samples. Food Addit Contam 2001 December;18(12):1088-93.
16) Meky FA, Turner PC, Ashcroft AE, Miller JD, Qiao YL, Roth MJ, Wild CP. Development of a urinary biomarker of human exposure to deoxynivalenol. Food Chem Toxicol 2003 February;41(2):265-73.
17) Young CL, Sclafani AG, Croley TR, Lemire SW, Barr JR. Simultaneous detection of trichothecene mycotoxins in human urine by LC-APCI/MS/MS. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005.
18) Kawamoto M, Page M. Notes from the field: Use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness-United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:157-158. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584707/pdf/157-158.pdf
19) National Institute for Occupational Safety and Health. Health hazard evaluation report: evaluation of health concerns in a public middle school—Virginia. Cincinnati, OH: US Dept, of Health and Human Services, CDC, NIOSH. Report HHE 2010-0045-3129. http://www.cdc.gov/niosh/hhe/reports/pdfs/2010-0045-3129.pdf
20) Centers for Disease Control and Prevention. Case Definitions for Chemical Poisoning. 2005 Jan 14. Report No.: 54(RR01). http://www.cdc.gov/mmwr/preview/mmwrhtml/ rr5401a1.htm
21) Bush RK, Portnoy JM, Saxon A, Terr AI, Wood RA. The medical effects of mold exposure. J Allergy Clin Immunology 2006;117(2):326-333. https://www.jacionline.org/article/S0091-6749(05)02591-1/pdf
22) Hurraß J, Wiesmüller GA. The German guideline on medical clinical diagnostics for indoor mold exposure: key messages. Allergo J Int 2024:1-4. https://link.springer.com/article/10.1007/s40629-024-00294-9
23) Seifert SA, Von ES, Jacobitz K, Crouch R, Lintner CP. Organic dust toxic syndrome: a review. J Toxicol Clin Toxicol 2003;41(2):185-93.
24) Poole JA, Zamora-Sifuentes JL, De las Vecillas L, Quirce S. Respiratory diseases associated with organic dust exposure." J Allergy Clin Immunology: In Practice 2024;12(8):1960-1971. DOI:https://doi.org/10.1016/j.jaip.2024.02.022
25) Claeson AS, Levin JO, Blomquist G, Sunesson AL. Volatile metabolites from microorganisms grown on humid building materials and synthetic media. J Environ Monit 2002;4(5):667-72.
26) Doty RL, Cometto-Muniz JE, Jalowayski AA, Dalton P, Kendal-Reed M, Hodgson M. Assessment of upper respiratory tract and ocular irritative effects of volatile chemicals in humans. Crit Rev Toxicol 2004;34(2):85-142.
27) Hurraß J, Teubel R, Fischer G, Heinzow B, Wiesmüller GA. What effect do mycotoxins, cell wall components, enzymes and other mold components and metabolites have on our health? Allergo J Int 2024:1-9. https://link.springer.com/article/10.1007/s40629-024-00295-8
28) National Institute for Occupational Safety and Health (NIOSH). Workplace Mold: Health Problems. https://www.cdc.gov/niosh/mold/health-problems/index.html
29) Borchers AT, Chang C, Gershwin ME. "Mold and human health: A reality check." Clin Rev Allergy Immunol 2017;52(3):305-322.
30) Rudert A, Portnoy J. Mold allergy: is it real and what do we do about it? Expert Rev Clin Immunol 2017;13(8):823-835.
31) Raulf M, Kespohl S. Skin tests, serological IgE detection, basophil test—what is available, useful and helps to clarify a mold allergy? Allergo J Int 2024;33(4):133-139.
32) Campbell, AW. "Molds, Mycotoxins, the Brain, the Gut and Misconceptions." Alternative Therapies in Health & Medicine 28, no. 3 (2022) 8-12.